Covid19
Conditions
Keywords
vaccination, efficacy, severe outcomes, mortality, variants, breakthrough infection, COVID-19, SARS-Cov-2 virus
Brief summary
With the FDA's emergency use authorization declaration in December of 2020, the Pfizer-BioNtech vaccine became the first of several vaccines to kick off the mass vaccination effort across the United States against CoronaVIrus Disease 2019 (COVID-19). Subsequently, Moderna as well as Johnson and Johnson both had vaccines receive emergency use authorization. While the Pfizer and the Moderna vaccines both utilize novel mRNA technology, Johnson and Johnson's vaccine uses a viral vector that has been used previously in both the approved European Ebola vaccine and a trial vaccine for HIV. However, none of these vaccine types have previously been approved in the United States. While preliminary data from safety and efficacy trials have shown positive results, actual-world data on its effectiveness is still lacking. Several small cohort studies and one large trial from Israel are currently the only insights into the actual rates of infection, hospitalization, and severe illness among vaccinated individuals. As COVID-19 variants, with the potential to reduce vaccine efficacy, continue to emerge worldwide, there is a need of more data regarding the real-world effectiveness of our current mass vaccination efforts. Vaccination efforts in the State of Michigan have been ongoing since December 2020. Given that approximately 33.7% of the state's population is either partially or fully vaccinated, it is unclear why the number of cases has risen so dramatically or if immunization efforts can help the situation. Given the current situation in the State of Michigan, this study will evaluate the efficacy of COVID-19 vaccination on rates of hospital visits and severe illness when breakthrough Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) infection occurs in a region with high incidence of variant strain disease.
Detailed description
A retrospective chart review of all patients presenting to Beaumont Health System emergency departments between December 15, 2020 and April 30, 2021 who tested positive for COVID-19 will be performed. The primary aim is to compare the rate of Emergency Department (ED) presentations/hospitalizations among unvaccinated, partially vaccinated, and fully vaccinated patients presenting to an emergency center (EC). Secondarily, the rates of individual clinical outcomes of COVID-19 infection for hospitalized patients will be compared among unvaccinated, partially vaccinated, and fully vaccinated patients, including the proportion of COVID-positive patients who develop severe disease, require admission to the hospital, and rates of those requiring intensive care unit (ICU) admission, mechanical ventilation, extracorporeal membrane oxygenation (ECMO), renal replacement therapy (RRT), supplemental oxygenation, or noninvasive ventilation, as well as the rate of in-hospital mortality and the hospital length of stay. Exploratory outcomes may include comparisons among fully-vaccinated individuals receiving each of the three types of vaccines, and investigation of demographic, epidemiological, clinical and laboratory predictors of hospitalization. For each individual, data collected will include vital signs (temperature, blood pressure, heart rate, respiratory rate, pulse oximetry), demographics (age, gender, existing medical conditions), home medications, chief complaint from emergency provider note, duration of symptoms in days at the time of presentation from emergency provider note, chest X-ray or chest computed tomography (CT) results, and laboratory values. For patients who were admitted, data collected will include initial hospital admission unit (regular medical or surgical floor, progressive floor, intensive care unit), change in unit type during admission, oxygen therapy (none, nasal cannula, supplemental high flow oxygen, ventilator), days on high flow oxygen, days on ventilator, specific inpatient medical therapies, laboratory values, imaging results, hospital length of stay, and disposition from hospital (home, rehabilitation unit, death).
Interventions
Full or partial reception of vaccine
Sponsors
Study design
Eligibility
Inclusion criteria
* All patients presenting to Beaumont Health emergency departments who have tested positive for COVID-19 between December 15, 2020 and April 30, 2021 with available vaccination data through state of Michigan registry.
Exclusion criteria
* Patients who have previously tested positive for COVID-19 prior to the study period will be excluded. * Patients with missing vaccine status will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Emergency Center (EC) Encounters and/or Hospitalizations With Positive COVID-19 Test | During the period from December 15, 2020 through April 30, 2021 (up to 5 months) | Number of participants with encounters at emergency center (EC) and /or hospitalizations with positive COVID-19 test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With ICU Admission | During hospitalization, from date of admission until May 15, 2021 (up to 5 months) | Number of patients admitted to ICU during hospital stay |
| Number of Patients Requiring Mechanical Ventilation | During EC visit or in-patient hospitalization, from date of presentation until May 15, 2021 (up to 5 months) | Number of patients who required mechanical ventilation |
| Number of Patients With In-hospital Mortality | During EC visit or in-patient hospitalization, from date of presentation until May 15, 2021 (up to 5 months) | Number of patients who died during EC visit or hospital admission |
| Number of Hospitalized Patients Requiring Extracorporeal Membrane Oxygenation (ECMO) | During hospitalization, from date of admission until May 15, 2021 (up to 5 months) | Number of hospitalized patients requiring ECMO |
| Number of Hospitalized Patients Requiring Renal Replacement Therapy (RRT) | During hospitalization, from date of presentation until May 15, 2021 (up to 5 months) | Number of hospitalized patients requiring RRT |
| Number of Patients With Severe Infection | During EC visit or hospitalization, from date of presentation until May 15, 2021 (up to 5 months) | Patient with any of the following: ICU admission, mechanical ventilation, or in-hospital mortality |
| Number of Hospitalized Patients Requiring Non-invasive Ventilation | During EC visit or hospitalization, from date of presentation until May 15, 2021 (up to 5 months) | Number of hospitalized patients requiring non-invasive ventilation |
| Number of Hospitalized Patients Requiring Vasopressors | During EC visit or hospitalization, from date of presentation until May 15, 2021 (up to 5 months) | Number of hospitalized patients with hypotension requiring vasopressors |
| Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | During the period from December 15, 2020 through May 15, 2021 (up to 5 months) | Number of patients discharged from in-patient hospital admission to home, skilled nursing facility, rehabilitation facility, or hospice. |
| Hospital Length of Stay | During the period from December 15, 2020 through May 15, 2021 (up to 5 months) | Number of days from admission after emergency center (EC) visit and positive COVID-19 test, until discharge |
| Number of Hospitalized Patients Requiring Supplemental Oxygen | During hospitalization, from date of admission until May 15, 2021 (up to 5 months) | Number of hospitalized patients requiring supplemental oxygen, by type |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Unvaccinated Unvaccinated individuals are defined as having positive laboratory COVID-19 testing with no record of immunization against COVID-19 or first-dose vaccination after symptom onset. | 10,880 |
| Partially Vaccinated Partially vaccinated individuals are defined as having positive laboratory COVID-19 testing and symptom onset after a single dose of either mRNA (Pfizer, Moderna) vaccine, or \< 14 days after the second dose of either mRNA vaccine (Pfizer, Moderna) or \< 14 days after the administration of the single dose of viral vector vaccine (Johnson & Johnson).
COVID-19 vaccine: Full or partial reception of vaccine | 825 |
| Fully Vaccinated Fully vaccinated individuals are defined as having positive laboratory testing for COVID-19 and symptom onset \>14 days since administration of second dose of either mRNA vaccine, or \>14 days since administration of viral vector vaccine (Johnson & Johnson).
COVID-19 vaccine: Full or partial reception of vaccine | 129 |
| Total | 11,834 |
Baseline characteristics
| Characteristic | Unvaccinated | Total | Fully Vaccinated | Partially Vaccinated |
|---|---|---|---|---|
| Age, Continuous | 52.1 years STANDARD_DEVIATION 18.2 | 53.0 years STANDARD_DEVIATION 18.2 | 70.3 years STANDARD_DEVIATION 16.4 | 62.5 years STANDARD_DEVIATION 15.3 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 3452 Participants | 3663 Participants | 13 Participants | 198 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 961 Participants | 1037 Participants | 8 Participants | 68 Participants |
| Race (NIH/OMB) White | 6467 Participants | 7134 Participants | 108 Participants | 559 Participants |
| Region of Enrollment United States | 10880 participants | 11834 participants | 129 participants | 825 participants |
| Sex: Female, Male Female | 5750 Participants | 6244 Participants | 69 Participants | 425 Participants |
| Sex: Female, Male Male | 5130 Participants | 5590 Participants | 60 Participants | 400 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 384 / 10,880 | 50 / 825 | 8 / 129 |
| other Total, other adverse events | 0 / 10,880 | 0 / 825 | 0 / 129 |
| serious Total, serious adverse events | 4,176 / 10,880 | 410 / 825 | 64 / 129 |
Outcome results
Number of Participants With Emergency Center (EC) Encounters and/or Hospitalizations With Positive COVID-19 Test
Number of participants with encounters at emergency center (EC) and /or hospitalizations with positive COVID-19 test
Time frame: During the period from December 15, 2020 through April 30, 2021 (up to 5 months)
Population: Study population is defined as numbers of participants presenting to EC or hospitalized.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Unvaccinated | Number of Participants With Emergency Center (EC) Encounters and/or Hospitalizations With Positive COVID-19 Test | 10880 Participants |
| Partially Vaccinated | Number of Participants With Emergency Center (EC) Encounters and/or Hospitalizations With Positive COVID-19 Test | 825 Participants |
| Fully Vaccinated | Number of Participants With Emergency Center (EC) Encounters and/or Hospitalizations With Positive COVID-19 Test | 129 Participants |
Hospital Length of Stay
Number of days from admission after emergency center (EC) visit and positive COVID-19 test, until discharge
Time frame: During the period from December 15, 2020 through May 15, 2021 (up to 5 months)
Population: Analysis performed only on patients admitted to hospital after EC visit
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Unvaccinated | Hospital Length of Stay | 7.2 days | Standard Deviation 7 |
| Partially Vaccinated | Hospital Length of Stay | 7.3 days | Standard Deviation 6.3 |
| Fully Vaccinated | Hospital Length of Stay | 7.0 days | Standard Deviation 5.2 |
Number of Hospitalized Patients Requiring Extracorporeal Membrane Oxygenation (ECMO)
Number of hospitalized patients requiring ECMO
Time frame: During hospitalization, from date of admission until May 15, 2021 (up to 5 months)
Population: Analysis performed only on patients hospitalized
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Unvaccinated | Number of Hospitalized Patients Requiring Extracorporeal Membrane Oxygenation (ECMO) | 4 Participants |
| Partially Vaccinated | Number of Hospitalized Patients Requiring Extracorporeal Membrane Oxygenation (ECMO) | 0 Participants |
| Fully Vaccinated | Number of Hospitalized Patients Requiring Extracorporeal Membrane Oxygenation (ECMO) | 0 Participants |
Number of Hospitalized Patients Requiring Non-invasive Ventilation
Number of hospitalized patients requiring non-invasive ventilation
Time frame: During EC visit or hospitalization, from date of presentation until May 15, 2021 (up to 5 months)
Population: Analysis performed only on patients hospitalized
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Unvaccinated | Number of Hospitalized Patients Requiring Non-invasive Ventilation | 428 Participants |
| Partially Vaccinated | Number of Hospitalized Patients Requiring Non-invasive Ventilation | 56 Participants |
| Fully Vaccinated | Number of Hospitalized Patients Requiring Non-invasive Ventilation | 10 Participants |
Number of Hospitalized Patients Requiring Renal Replacement Therapy (RRT)
Number of hospitalized patients requiring RRT
Time frame: During hospitalization, from date of presentation until May 15, 2021 (up to 5 months)
Population: Analysis performed only on patients hospitalized
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Unvaccinated | Number of Hospitalized Patients Requiring Renal Replacement Therapy (RRT) | 130 Participants |
| Partially Vaccinated | Number of Hospitalized Patients Requiring Renal Replacement Therapy (RRT) | 14 Participants |
| Fully Vaccinated | Number of Hospitalized Patients Requiring Renal Replacement Therapy (RRT) | 0 Participants |
Number of Hospitalized Patients Requiring Supplemental Oxygen
Number of hospitalized patients requiring supplemental oxygen, by type
Time frame: During hospitalization, from date of admission until May 15, 2021 (up to 5 months)
Population: Analysis performed only on patients hospitalized
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Unvaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | Mechanical ventilation | 395 Participants |
| Unvaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | Non-invasive ventilation | 428 Participants |
| Unvaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | Nasal canula | 2563 Participants |
| Unvaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | High flow oxygen | 656 Participants |
| Unvaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | none | 1208 Participants |
| Partially Vaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | Non-invasive ventilation | 56 Participants |
| Partially Vaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | Nasal canula | 231 Participants |
| Partially Vaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | High flow oxygen | 67 Participants |
| Partially Vaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | Mechanical ventilation | 42 Participants |
| Partially Vaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | none | 119 Participants |
| Fully Vaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | none | 31 Participants |
| Fully Vaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | Mechanical ventilation | 6 Participants |
| Fully Vaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | Nasal canula | 38 Participants |
| Fully Vaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | Non-invasive ventilation | 10 Participants |
| Fully Vaccinated | Number of Hospitalized Patients Requiring Supplemental Oxygen | High flow oxygen | 10 Participants |
Number of Hospitalized Patients Requiring Vasopressors
Number of hospitalized patients with hypotension requiring vasopressors
Time frame: During EC visit or hospitalization, from date of presentation until May 15, 2021 (up to 5 months)
Population: Analysis performed only on patients hospitalized
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Unvaccinated | Number of Hospitalized Patients Requiring Vasopressors | 348 Participants |
| Partially Vaccinated | Number of Hospitalized Patients Requiring Vasopressors | 45 Participants |
| Fully Vaccinated | Number of Hospitalized Patients Requiring Vasopressors | 6 Participants |
Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice.
Number of patients discharged from in-patient hospital admission to home, skilled nursing facility, rehabilitation facility, or hospice.
Time frame: During the period from December 15, 2020 through May 15, 2021 (up to 5 months)
Population: Analysis performed only on patients who were admitted to hospital
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Unvaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Rehabilitation Institute | 72 Participants |
| Unvaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Home | 4110 Participants |
| Unvaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Skilled Nursing Home | 514 Participants |
| Unvaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Hospice | 125 Participants |
| Unvaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Transferred to another facility | 50 Participants |
| Unvaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Death | 379 Participants |
| Partially Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Death | 49 Participants |
| Partially Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Transferred to another facility | 4 Participants |
| Partially Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Home | 368 Participants |
| Partially Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Hospice | 21 Participants |
| Partially Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Rehabilitation Institute | 7 Participants |
| Partially Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Skilled Nursing Home | 66 Participants |
| Fully Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Rehabilitation Institute | 0 Participants |
| Fully Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Skilled Nursing Home | 20 Participants |
| Fully Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Death | 8 Participants |
| Fully Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Hospice | 6 Participants |
| Fully Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Home | 61 Participants |
| Fully Vaccinated | Number of Patients Discharged From Hospital to Home, Skilled Nursing Facility, Rehabilitation Facility, or Hospice. | Transferred to another facility | 0 Participants |
Number of Patients Requiring Mechanical Ventilation
Number of patients who required mechanical ventilation
Time frame: During EC visit or in-patient hospitalization, from date of presentation until May 15, 2021 (up to 5 months)
Population: Analysis performed on all patients presenting to EC including those hospitalized
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Unvaccinated | Number of Patients Requiring Mechanical Ventilation | 398 Participants |
| Partially Vaccinated | Number of Patients Requiring Mechanical Ventilation | 42 Participants |
| Fully Vaccinated | Number of Patients Requiring Mechanical Ventilation | 6 Participants |
Number of Patients With ICU Admission
Number of patients admitted to ICU during hospital stay
Time frame: During hospitalization, from date of admission until May 15, 2021 (up to 5 months)
Population: Analysis performed on all patients presenting to EC including those hospitalized
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Unvaccinated | Number of Patients With ICU Admission | 619 Participants |
| Partially Vaccinated | Number of Patients With ICU Admission | 75 Participants |
| Fully Vaccinated | Number of Patients With ICU Admission | 14 Participants |
Number of Patients With In-hospital Mortality
Number of patients who died during EC visit or hospital admission
Time frame: During EC visit or in-patient hospitalization, from date of presentation until May 15, 2021 (up to 5 months)
Population: Analysis performed on all patients presenting to EC including those hospitalized
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Unvaccinated | Number of Patients With In-hospital Mortality | 384 Participants |
| Partially Vaccinated | Number of Patients With In-hospital Mortality | 50 Participants |
| Fully Vaccinated | Number of Patients With In-hospital Mortality | 8 Participants |
Number of Patients With Severe Infection
Patient with any of the following: ICU admission, mechanical ventilation, or in-hospital mortality
Time frame: During EC visit or hospitalization, from date of presentation until May 15, 2021 (up to 5 months)
Population: Analysis performed on all patients presenting to EC including those hospitalized
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Unvaccinated | Number of Patients With Severe Infection | 733 Participants |
| Partially Vaccinated | Number of Patients With Severe Infection | 85 Participants |
| Fully Vaccinated | Number of Patients With Severe Infection | 16 Participants |